 NEW YORK, June 09, 2021 GLOBE NEWSWIRE -- Intercept Pharmaceuticals, Inc. Nasdaq:ICPT, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research Development and Chief Medical Officer. 